Evogene
EVGN
28 hedge funds and large institutions have $760K invested in Evogene in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.
54% more capital invested
Capital invested by funds: $494K → $760K (+$266K)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 27 → 28 (+1)
0.02% less ownership
Funds ownership: 0.19% → 0.17% (-0.02%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$67.6K |
| 2 |
Jane Street
New York
|
+$18.6K |
| 3 |
VF
Virtu Financial
New York
|
+$18.5K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$13.1K |
| 5 |
QC
Quent Capital
New York
|
+$8.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$50K |
| 2 |
Renaissance Technologies
New York
|
-$49.2K |
| 3 |
Morgan Stanley
New York
|
-$30.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$30.3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$15K |
EVGN Hedge Fund Activity: Q2 2023 in Review
28 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2023, worth a combined $760K — up 54% from $494K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVGN positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $67.6K. The largest seller was Millennium Management, exiting entirely with an estimated $50K sold.
- 28 institutional investors held Evogene (EVGN) as of Q2 2023, up from 27 in Q1 2023.
- Funds reported $760K of Evogene stock for Q2 2023, up 54% quarter-over-quarter.
- 6 funds opened new Evogene positions in Q2 2023 and 5 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q2 2023 was Silverarc Capital Management, an estimated $67.6K added.
- The largest Evogene seller in Q2 2023 was Millennium Management, an estimated $50K sold.
Based on aggregated 13F filings for Q2 2023.